Biomerica has received the United Arab Emirates (UAE) Ministry of Health and Prevention approval for its Fortel Ulcer Test for at-home usage.
The ten-minute rapid test is said to identify antibodies to Helicobacter pylori (H. pylori), a bacterium linked to various gastrointestinal conditions such as dyspepsia, peptic ulcers, and a substantial number of gastric cancer cases.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With the new approval, UAE residents can now perform the test at home.
According to the company, H. pylori impacts an estimated 41% of the UAE’s population, with certain demographics experiencing a higher incidence.
Without treatment, up to 20% of those infected could develop severe health issues. Infection involving the bacterium is notably associated with up to 80% of gastric cancer cases.
The World Health Organization (WHO) has classified it as a Class 1 carcinogen, highlighting it as a significant antibiotic-resistant bacterial threat.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBiomerica is collaborating with local distributors and healthcare providers to distribute the ulcer test through clinics, online channels, and pharmacies. This move is part of the company’s expansion in the Middle East, following the regional introduction of the EZ Detect Colon Disease Test and other early detection diagnostics.
Biomerica CEO Zack Irani said: “With this home-use approval, we’re giving people direct access to a reliable tool for early detection of a dangerous infection that could result in serious complications.
“This can help drive earlier and more effective medical treatment and potentially save lives.”
The company is focusing on providing diagnostic tools that facilitate early disease identification, aiming to enhance patient outcomes.
In January 2025, Biomerica’s Fortel prostate-specific antigen (PSA) screening test, which aids in the early detection of prostate cancer, received approval from the UAE Ministry of Health and Prevention.
